Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24110255 | 0.86 | HTR2C (0.35) | GRM2HTR2CNR3C1NR3C2PGR | |
| SCHEMBL24110313 | 0.85 | NR3C1 (0.36) | GRM2HTR2CNR3C1NR3C2PGR | |
| SCHEMBL24110244 | 0.82 | GRM2 (0.33) | GRM2HTR2CNR3C1NR3C2PGR | |
| SCHEMBL24109778 | 0.82 | HTR2C (0.55) | HTR2CNR3C1NR3C2PGRPRMT5 | |
| SCHEMBL24110256 | 0.81 | NR3C1 (0.35) | GRM2HTR2CNR3C1NR3C2PGR | |
| SCHEMBL24110260 | 0.80 | HTR2C (0.37) | GRM2HTR2CKRAS | |
| SCHEMBL24110285 | 0.78 | HTR2A (0.33) | HTR2C | |
| SCHEMBL24110258 | 0.77 | HTR2A (0.35) | HTR2CNR3C1NR3C2PGR | |
| SCHEMBL24110252 | 0.74 | NR3C1 (0.33) | HTR2CNR3C1NR3C2PGR | |
| SCHEMBL24109773 | 0.74 | HTR2C (0.51) | HTR2CNR3C1NR3C2PGRPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2021252692-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | GAP43, SLC18A2, PNMT | GRM2 27/4885HTR2C 35/4885NR3C1 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.